Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
QNCX 
Quince Therapeutics, Inc. (QNCX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: QNCX (4-star) is a STRONG-BUY. BUY since 10 days. Simulated Profits (-4.62%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.5
1 Year Target Price $7.5
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 72.05% | Avg. Invested days 34 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 99.91M USD | Price to earnings Ratio - | 1Y Target Price 7.5 |
Price to earnings Ratio - | 1Y Target Price 7.5 | ||
Volume (30-day avg) 4 | Beta 1.08 | 52 Weeks Range 0.72 - 2.45 | Updated Date 10/19/2025 |
52 Weeks Range 0.72 - 2.45 | Updated Date 10/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.1 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -19.33% | Return on Equity (TTM) -167.04% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 70870628 | Price to Sales(TTM) - |
Enterprise Value 70870628 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.44 | Shares Outstanding 53713798 | Shares Floating 44783879 |
Shares Outstanding 53713798 | Shares Floating 44783879 | ||
Percent Insiders 11.09 | Percent Institutions 23.1 |
Upturn AI SWOT
Quince Therapeutics, Inc.
Company Overview
History and Background
Quince Therapeutics, Inc., formerly Cortexyme, Inc., is a biopharmaceutical company focused on acquiring, developing, and commercializing innovative precision therapeutics targeting debilitating diseases with significant unmet medical needs. Founded in 2012, the company initially focused on Alzheimer's disease but has since broadened its pipeline through acquisitions and strategic partnerships.
Core Business Areas
- Bone Health: Development of therapeutics for bone diseases and conditions. This includes pipeline products for osteogenesis imperfecta and other bone disorders.
- Acquired Programs: Focus on developing therapeutic candidates obtained through acquisitions, often targeting novel mechanisms or disease areas.
Leadership and Structure
The leadership team includes Dirk Thye as CEO, and the company operates with a traditional organizational structure for a biotechnology firm, involving research and development, clinical operations, and commercial strategy departments. The board of directors provides oversight and strategic guidance.
Top Products and Market Share
Key Offerings
- Berywam: An investigational anabolic therapy in Phase 2 development for adults with osteogenesis imperfecta (OI). Market share is not applicable since it is not commercialized yet. Competitors in the OI space include Ascendis Pharma (ASND) with TransCon CNP and potential gene therapies in early stages of development.
- QS9003: Anabolic therapy in Phase 1 development for children with osteogenesis imperfecta (OI). Market share is not applicable since it is not commercialized yet. Competitors in the OI space include Ascendis Pharma (ASND) with TransCon CNP and potential gene therapies in early stages of development.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high risk and high reward, driven by innovation and regulatory hurdles. Key trends include precision medicine, gene therapy, and increased focus on rare diseases.
Positioning
Quince Therapeutics, Inc. is positioned as a company developing precision therapeutics for niche markets with high unmet medical needs. Their focus is on bone diseases.
Total Addressable Market (TAM)
The TAM for rare bone diseases is estimated to be in the billions of dollars, considering the high cost of orphan drugs. Quince Therapeutics, Inc. aims to capture a significant portion of this market with their targeted therapies.
Upturn SWOT Analysis
Strengths
- Focus on niche markets with high unmet needs
- Innovative precision therapeutic approach
- Experienced management team
- Potential for breakthrough therapies
Weaknesses
- Limited pipeline depth
- High dependence on clinical trial success
- Financial resources constraints
- Lack of commercialized products
Opportunities
- Potential for partnerships and collaborations
- Expansion into new therapeutic areas
- Accelerated regulatory pathways for orphan drugs
- Positive clinical trial results
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from larger pharmaceutical companies
- Patent expirations
Competitors and Market Share
Key Competitors
- ASND
- BMY
- LLY
Competitive Landscape
Quince Therapeutics, Inc. is a smaller player compared to large pharmaceutical companies. Their competitive advantage lies in their niche focus and precision therapeutic approach, but they face challenges from larger companies with greater resources.
Major Acquisitions
Biopharmex
- Year: 2024
- Acquisition Price (USD millions): 57.9
- Strategic Rationale: Acquisition of Biopharmex added QS9003 to Quince's pipeline
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily reflected in the expansion of its pipeline and strategic acquisitions.
Future Projections: Future growth depends on the success of their clinical trials and regulatory approvals. Analyst estimates vary widely, reflecting the inherent risk in the biotech sector.
Recent Initiatives: Recent initiatives include advancing their pipeline programs and exploring potential acquisitions or partnerships to expand their therapeutic focus.
Summary
Quince Therapeutics, Inc. is a development-stage biopharmaceutical firm focusing on rare bone diseases, which provides focused growth potential. Their success heavily relies on clinical trials and regulatory approvals, and the fact they are competing with large pharmaceutical companies is a threat. The company shows focused approach with a strong R&D pipeline that are being supplemented by smart acquisitions.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry databases
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is an estimate and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Quince Therapeutics, Inc.
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2019-05-09 | CEO, Chief Medical Officer & Director Dr. Dirk Thye M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 36 | Website https://www.quincetx.com |
Full time employees 36 | Website https://www.quincetx.com | ||
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.